logo
What's Right With Schools: Bristol students raise money to help Man with ALS get new service dog

What's Right With Schools: Bristol students raise money to help Man with ALS get new service dog

Yahoo03-06-2025
BRISTOL, Conn. (WTNH) — A classroom is coming together to make a difference in someone's life. They're getting creative and raising money for a cause.
Step into the hallway of St. Matthew School in Bristol. Students are on a mission, pushing a cart full of items they've made.
What's Right with Schools: Students in Columbia learn about future career opportunities
'My friends and I we made bracelets…And we crocheted some headbands and cute little animals and we just made some slime and liked selling it to the kids,' Fifth grader Emily Mullins said.
It's a real business they came up with.
Meet Swanson, the loyal service dog who dedicated his life to Stuart Sherman, who lives with ALS.
'He was diagnosed with ALS 12 years ago. And honestly, I thought he wouldn't be here. As the diagnosis said, 3-5 years, we'd lose him,' Celeste Valenti Sherman, Stuart's wife, said.
She credits prayer and perhaps this partner with paws, who has him outliving that dark diagnosis.
'I take care of her… She takes care of me,' Sherman said.
He was once self-conscious about going out in public with his physical changes, but the dog first gave him confidence.
'He hand cycles marathons, he goes to the gym every day. He's done what, 7 marathons, he's training for a half in June,' she said. 'I always say he's in love with another woman, and I don't care, that's fine.'
But sadly, Swanson is tired. Now they need to raise money for another service animal so she can retire.
To give you some perspective, service dogs like this typically retire at the age of 10 or 11, because of a shortage. Swanson is 12, so it's time for her to live out her golden years.
That's where Jessica Martineau's fifth-grade class comes in. They met the pair and wanted to help.
'They wanted to help Swanson retire and still have Stuart have another puppy,' Jessica Martineau, a fifth-grade teacher, said. 'On rainy days, cold days, instead of choosing Legos or free draw. These kids were making bracelets, crocheting animals for the store.'
'I made some slime like I would help with the prices and all the other stuff,' Michael Marino said.
The goal was $500, and the result was double that.
'We would like to give Stuart and Celeste a check of $1,000 from the fifth-grade class,' Martineau said.
Hard work, crafting, and selling. A gift from the heart to a lovable pair.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid
Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid

Yahoo

time4 hours ago

  • Yahoo

Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid

We recently published . Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best healthcare stocks. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotechnology company integrating artificial intelligence (AI), machine learning, and high-throughput biology to accelerate drug discovery, with a focus on oncology and rare diseases. Its proprietary Recursion OS platform streamlines therapeutic identification and development. In July–August 2025, the company acquired full rights to REV102, an oral ENPP1 inhibitor from Rallybio, aimed at treating hypophosphatasia (HPP), a rare genetic disorder with no approved oral disease-modifying therapies. This acquisition expands Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)'s rare disease pipeline and gives it full control over a promising preclinical program. At the same time, the business streamlined its portfolio by discontinuing or pausing several programs, narrowing its focus to six active candidates, four in oncology and two in rare diseases. Its innovative AI-driven platform and pipeline have also drawn attention from investors seeking the best healthcare stocks in biotech. The corporation continues to expand its AI-driven capabilities, most notably through a collaboration with MIT to advance the Boltz-2 AI model on its BioHive-2 platform. This initiative aims to accelerate molecular discovery and synthesis, potentially shortening the path from discovery to clinical trials. The rollout of Recursion OS 2.0 and new partnerships with biopharma and data science firms further enhance its discovery and development capabilities. Copyright: dolgachov / 123RF Stock Photo Upcoming milestones in 2025 include multiple clinical trial initiations and data readouts, such as REC-617, a CDK7 inhibitor in oncology, and REC-4881 for familial adenomatous polyposis. Following its late 2024 merger with Exscientia, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)'s oncology pipeline has broadened, with several candidates expected to advance into human studies. While we acknowledge the potential of RXRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio

GoodRx (GDRX) Lifts Guidance as Pharma Partnerships Drive Double-Digit Growth
GoodRx (GDRX) Lifts Guidance as Pharma Partnerships Drive Double-Digit Growth

Yahoo

time4 hours ago

  • Yahoo

GoodRx (GDRX) Lifts Guidance as Pharma Partnerships Drive Double-Digit Growth

We recently published . GoodRx Holdings, Inc. (NASDAQ:GDRX) is one of the best healthcare stocks. GoodRx Holdings, Inc. (NASDAQ:GDRX) is a leading U.S. digital healthcare platform that helps consumers compare prescription drug prices and access discounts, while also expanding into telehealth and other healthcare services. A major recent focus is the company's growth in pharma manufacturer solutions, where it partners with drug makers for targeted advertising and patient access programs. In Q2 2025, revenue from this segment rose 32%, prompting GoodRx to raise its full-year growth forecast from 20% to 30%. This shift diversifies its business beyond traditional prescription savings cards and strengthens its role as a key marketing partner for pharmaceutical companies. Copyright: zneb076 / 123RF Stock Photo GoodRx Holdings, Inc. (NASDAQ:GDRX) is also broadening its consumer offerings through subscription-based services, including a new program for affordable erectile dysfunction medications (Sildenafil and Tadalafil). These initiatives support its mission of lowering out-of-pocket drug costs while enhancing direct-to-consumer healthcare access. Its telehealth platform remains an important but underutilized growth channel, with potential for further expansion. Additionally, GoodRx Holdings, Inc. (NASDAQ:GDRX) is undergoing a brand relaunch and implementing targeted marketing strategies to boost engagement and market share. While we acknowledge the potential of GDRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

LifeStance Health (LFST) Accelerates Growth with AI-Enabled Operations and Clinician Expansion
LifeStance Health (LFST) Accelerates Growth with AI-Enabled Operations and Clinician Expansion

Yahoo

time4 hours ago

  • Yahoo

LifeStance Health (LFST) Accelerates Growth with AI-Enabled Operations and Clinician Expansion

We recently published . LifeStance Health Group, Inc. (NASDAQ:LFST) is one of the best healthcare stocks. LifeStance Health Group, Inc. (NASDAQ:LFST) stands fifth among the best healthcare stocks. It is one of the largest outpatient mental health providers in the U.S. that operates over 550 locations across 33 states with nearly 7,500 clinicians, offering a hybrid of in-person and telehealth care (about 70% virtual). The company primarily serves patients with commercial insurance and focuses on expanding access to affordable behavioral health services. In 2025, LifeStance Health Group, Inc. (NASDAQ:LFST) accelerated its digital transformation, with a strong emphasis on artificial intelligence (AI) to improve efficiency. AI tools are being deployed in revenue cycle management, patient scheduling, and soon, clinician documentation, aimed at reducing administrative burdens and improving satisfaction. The appointment of Vaughn Paunovich as CTO marks a renewed push toward technology-driven operations. As part of this effort, the business is reviewing new electronic health record (EHR) platforms, with a decision expected by late 2025. Operational upgrades also include a digital patient check-in tool, improved HR and credentialing systems, and enhanced payer engagement platforms. These changes are designed to strengthen operational foundations for sustainable growth rather than rapid, acquisition-heavy expansion. Copyright: racorn / 123RF Stock Photo Q2 2025 saw an 11% increase in clinicians (173 added), supported by scheduling and productivity technologies that have improved retention and patient management. LifeStance Health Group, Inc. (NASDAQ:LFST) expects these digital and AI investments to yield significant productivity gains and improved patient care from 2026 onward, positioning the company as a leader in next-generation, tech-enabled mental health services. While we acknowledge the potential of LFST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store